Alliance announces FDA approval of atezolizumab based on results from the Phase III ATOMIC trial for patients with Stage III dMMR colon cancer
Prognostic nutritional index predicts outcomes in hepatocellular carcinoma treated with atezolizumab and bevacizumab - EurekAlert!
Alliance presents results from phase III ATOMIC trial combining atezolizumab with chemotherapy for patients with stage III dMMR colon cancer at ASCO 2025 - EurekAlert!
